• Donald Davis

AMR Antimicrobial Resistance New Technologies

One of my first podcasts was an interview of Dr. Ethan Mann. With that release, I thought that I would spend a few minutes describing one of the key topics: Antimicrobial Resistance.

According to the WHO (World Health Organization), Antimicrobial Resistance (AMR) happens “when microorganisms (such as bacteria, fungi, viruses, and parasites) change when they are exposed to antimicrobial drugs (such as antibiotics, antifungals, antivirals, antimalarials, and anthelmintics).” The medicines that we normally take become ineffective and in some cases this resistance is called a “superbug”.

According to de Kraker et al (2016) in 2050 10 Million people will die every year due to AMR. This would be in comparison to cancer which is estimated to be 8.2 Million deaths by 2050 (Tagliabue & Rappuoli, 2018). This topic continues to plague mankind and differing solutions should be considered.

Companies like Sharklet Technologies have developed therapies for inhibiting bacterial growth. See more at: https://www.sharklet.com/

As we enter the post-antibiotic era, companies like Validus Cellular Therapeutics are creating a pipeline of Mesenchymal Stem Cells (MSC) to fight infections. See more at: https://validustherapeutics.com/

AMR is a global issue that needs specific focus so that we will not continue to lose lives to antimicrobial infections. Developing better tests and treatments is a mission that will save lives in our very near future.



de Kraker MEA, Stewardson AJ, Harbarth S (2016) Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? PLoS Med 13(11): e1002184. https://doi.org/10.1371/journal.pmed.1002184

Tagliabue, A., & Rappuoli, R. (2018). Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top. Frontiers in immunology, 9, 1068. https://doi.org/10.3389/fimmu.2018.01068

7 views0 comments

Recent Posts

See All